Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Down 5.0 %

NASDAQ CARA opened at $0.31 on Wednesday. Cara Therapeutics has a 12-month low of $0.24 and a 12-month high of $1.31. The company has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.40. The stock has a market cap of $17.06 million, a P/E ratio of -0.15 and a beta of 0.68.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. As a group, sell-side analysts forecast that Cara Therapeutics will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Cara Therapeutics

A number of large investors have recently bought and sold shares of CARA. XTX Topco Ltd purchased a new position in Cara Therapeutics during the 3rd quarter worth approximately $29,000. FMR LLC increased its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares during the period. Finally, Disciplined Growth Investors Inc. MN raised its holdings in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.